

# **Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis**

### A study protocol

Antoni Soriano-Arandes, MD, PhD<sup>a</sup>, Joan A. Caylà, MD, PhD<sup>b</sup>, Alessandra Queiroga Gonçalves, PhD<sup>c,d</sup>, Àngels Orcau, MD<sup>e,f</sup>, Antoni Noguera-Julian, MD, PhD<sup>f,g,h,i</sup>, Emma Padilla, MD, PhD<sup>j</sup>, Elisabet Solà-Segura, MD<sup>k</sup>, Neus Rius Gordillo, MD, MSc<sup>l</sup>, María Espiau, MD, PhD<sup>a</sup>, Mónica G. García-Lerín, MD<sup>m</sup>, Maria Àngels Rifà-Pujol, MD<sup>n</sup>, Jordi Gómez i Prat, MD, MSc<sup>o</sup>, Esperança Macia-Rieradevall, MD, MSc<sup>p</sup>, Andrea Martin-Nalda, MD<sup>a,q,r</sup>, Maria Eril-Rius, MD<sup>s</sup>, José Santos Santiago, MD, MSc<sup>t</sup>, Lídia Busquets-Poblet, MD<sup>u</sup>, Raisa Morales Martínez, MD<sup>t</sup>, Tomàs Maria Pérez-Porcuna, MD, PhD<sup>m,v,\*</sup>

#### Abstract

**Introduction:** Tuberculosis (TB) is a global infectious disease. In low-incidence countries, paediatric TB affects mostly immigrant children and children of immigrants. We hypothesize that these children are at risk of exposure to *Mycobacterium tuberculosis* when they travel to the country of origin of their parents to visit friends and relatives (VFR). In this study, we aim to estimate the incidence rate and risk factors associated to latent tuberculosis infection (LTBI) and TB in VFR children.

**Methods and analysis:** A prospective study will be carried out in collaboration with 21 primary health care centres (PCC) and 5 hospitals in Catalonia, Spain. The study participants are children under 15 years of age, either immigrant themselves or born to immigrant parents, who travel to countries with high incidence of TB ( $\geq$  40 cases/100,000 inhabitants). A sample size of 492 children was calculated. Participants will be recruited before traveling, either during a visit to a travel clinic or to their PCC, where a questionnaire including sociodemographic, epidemiological and clinical data will be completed, and a tuberculin skin test (TST) will be performed and read after 48 to 72 hours; patients with a positive TST at baseline will be excluded. A visit will be scheduled eight to

This work was supported by a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2016 call under the Health Strategy Action 2013–2016, within the National Research Program oriented to Societal Challenges, within the Technical, Scientific and Innovation Research National Plan 2013–2016, with reference PI16/00314, co-funded with European Union ERDF funds (European Regional Development Fund); by the Departament de Salut of the Generalitat de Catalunya, in the call for the year 2017 of granting grants of the Strategic Plan for Research and Innovation in Health (PERIS) 2016–2020, modalitat Intensificació de Facultatius Especialistes, with the file code SLT006/17/144; by the Spanish Society of Pneumology and Thoracic Surgery (grant number 90/ 2015). The funders will not have any authority over any of the activities of the project.

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

<sup>a</sup> Unitat de Patologia Infecciosa i Immunodeficiències Pediàtriques, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, <sup>b</sup> Fundació de la Unitat d'Investigació en Tuberculosi de Barcelona, Barcelona, <sup>c</sup> Unitat de Suport a la Recerca Terres de l'Ebre, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), <sup>d</sup> Unitat Docent de Medicina de Familia i Comunitària, Tortosa-Terres de l'Ebre, Institut Català de la Salut, Tortosa, Tarragona, <sup>e</sup> Servei d'epidemiologia, Agència de Salut Pública de Barcelona, Barcelona, <sup>f</sup> Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, <sup>g</sup> Malatties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Unitat d'Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica, Hospital Sant Joan de Déu, Barcelona, <sup>h</sup> Departament de Pediatria, Universitat de Barcelona, Barcelona, <sup>I</sup>Red de Investigación Translacional en Infectología Pediátrica (RITIP), Madrid, <sup>j</sup> Àrea de Microbiologia de Catlab, Terrassa, <sup>k</sup> Equip d'Atenció Primària Vic Nord, Institut Català de la Salut, Vic, <sup>I</sup>Servei de Pediatria Hospital Universitari Sant Joan de Reus, Reus, <sup>m</sup> Atenció Primària, Fundació Assistencial Mútua Terrassa, Terrassa, <sup>n</sup> Equip d'Atenció Primària Tona, Institut Català de la Salut, Tona, <sup>o</sup> Equip de Salut Pública i Comunitària de la Unitat de Salut Internacional Drassanes-Hospital Universitari Vall d'Hebron, Servei de Medicina Preventiva de Vall d'Hebron, Barcelona, <sup>p</sup> Equip d'Atenció primària de la Unitat de Salut, Manlleu, <sup>q</sup> Grup de recerca infecció en el pacient pediàtric immunodeprimit, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, <sup>s</sup> Equip d'Atenció primària La Vall de la Salut, Manlleu, <sup>q</sup> Grup de recerca infecció en el pacient pediàtric immunodeprimit, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, <sup>s</sup> Equip d'Atenció primària La Vall del Ges, Institut Català

\* Correspondence: Tomàs Maria Pérez-Porcuna, Atenció Primària, Fundació Assistencial Mútua Terrassa, Terrassa, Spain (e-mail: tomas.perez.porcuna@gmail.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Soriano-Arandes A, Caylà JA, Gonçalves AQ, Orcau À, Noguera-Julian A, Padilla E, Solà-Segura E, Gordillo NR, Espiau M, García-Lerín MG, Rifà-Pujol MÀ, Jordi Gómez i Prat, Macia-Rieradevall E, Martin-Nalda A, Eril-Rius M, Santos Santiago J, Busquets-Poblet L, Martínez RM, Pérez-Porcuna TM. Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis: a study protocol. Medicine 2020;99:36(e22015).

Received: 25 July 2020 / Accepted: 31 July 2020

http://dx.doi.org/10.1097/MD.000000000022015

twelve-weeks after their return to perform a TST and a QuantiFERON-TB Gold Plus test. The incidence rate of LTBI will be estimated per individual/month and person/year per country visited, and also by age-group.

**Ethics and dissemination:** The study protocol was approved by the Clinical Research Ethics Committee of the Hospital Universitari Mútua Terrassa (code 02/16) and the Clinical Research Ethics Committee of the Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (code P16/094). Articles will be published in indexed scientific journals.

Trial registration: Clinical-Trials.gov: NCT04236765

**Abbreviations:** LTBI = latent infection by *M. tuberculosis*, PCC = primary health care centres, QFT-Plus = QuantiFERON-TB Gold Plus, TB = Tuberculosis, TST = tuberculin skin test, VFR = visit friends and relatives.

Keywords: children, incidence, interferon-gamma release assay, latent tuberculosis, travel-related infection, tuberculin test, tuberculosis

#### 1. Introduction

It is estimated that one third of the world population is infected with *Mycobacterium tuberculosis* and that 5% to 10% of those infected will develop tuberculosis (TB) during their lifetime.<sup>[1]</sup> Current global figures indicate that 10 million people develop TB every year, of which 1.1 million are children.<sup>[2]</sup>

It is important to underscore that children have a greater risk of developing active TB after primary infection, especially before their fifth birthday.<sup>[3]</sup> Significantly, children infected with *M tuberculosis* that do not develop the disease and that do not receive preventive treatment will constitute a reservoir of TB in the future.<sup>[4]</sup> Consequently, the identification and administration of preventive treatment to children with latent tuberculosis infection (LTBI) are critical to the global TB control and eradication efforts.<sup>[5–7]</sup>

In countries with low TB incidence, the burden of disease is notably higher in the immigrant than in the autochthonous population.<sup>[8–10]</sup> Importantly, this higher incidence of tuberculosis persists beyond the first years after arrival to the host country.<sup>[11,12]</sup> In fact, most new paediatric TB cases in western countries occur in immigrant children and autochthonous children born to immigrant parents.<sup>[5,8,9]</sup>

In Europe, TB and hepatitis C are the main imported infections among the immigrant population.<sup>[13]</sup> The recent increase in international travel of immigrants to their countries of origin to visit friends and relatives (VFR)<sup>[14–16]</sup> and subsequent exposure to *M tuberculosis* in countries with incidences of TB higher than in the host countries could partially explain the differences in incidence between children of immigrant families and children from the autochthonous population.<sup>[17]</sup> It seems plausible to associate travel-related factors with risk of contagion, including the intensity of transmission (proportional to the local TB incidence), the relationship and contact with the local population, the duration of the stay, and individual host factors.<sup>[18]</sup>

However, the risk of LTBI is difficult to estimate, firstly because of the lack of a gold standard for the diagnosis, and secondly due to the long incubation period before the development of the TB disease, specially in people over 5 years of age.<sup>[18]</sup>

Due to the little evidence on the risk factors associated to LTBI and TB in VFR children, it is crucial to elucidate the epidemiology of TB in the immigrant population and their children to better inform public health policies aimed at reducing the number of TB cases.<sup>[19]</sup>

The objectives of this study are (1) to estimate the incidence rate of LTBI and TB in paediatric VFR travellers when returning from the countries of origin of their parents and (2) to identify risk factors associated with LTBI and TB.

#### 2. Methods and design

An interventional, single group assignment, multicentre study will be carried out from June 2017 to December 2020 in Catalonia. The incidence rate of LTBI/TB in Catalonia is 12.6 cases/100,000 inhabitants and 36.3 cases/100,000 inhabitants among the general and the immigrant population, respectively.<sup>[20]</sup> BCG vaccination is not included in the national programme of immunization.

#### 2.1. Setting and participants

Participants of the study are children that meet the inclusion criteria, attended at any of the 5 pre-travel health clinics or at any of the 21 primary health centres (PCC) involved in the study.

#### 2.1.1. Inclusion criteria (all criteria must be met).


- Children less than 15 years of age, either immigrants or children born in Spain to immigrant parents.
- Children with at least one of the parents from a high TB incidence country. We define "high TB incidence country" as a country with a TB incidence rate 3 times higher than in Catalonia, namely 40 cases/100,000 inhabitants or greater.<sup>[6,20]</sup> Countries with official reports describing an incidence less than the value proposed but with some regions with ≥40 cases/100,000 inhabitants will also be considered of high incidence (Fig. 1 and Table 1).
- Children travelling and accompanying at least one of the parents to their country of origin.
- The duration of the trip must last a minimum of 21 days.
- Informed consent must be obtained from the parents or legal guardian.

#### 2.1.2. Exclusion criteria.

- Children with previous TB or LTBI.
- Tourist travel staying in hotels and/or resorts with scarce contact with the autochthonous population.
- Children with primary or secondary immunodeficiency due to treatment with corticosteroids, transplantation, treatment with anti-tumour necrosis factor, or chronic renal insufficiency.
- Children with congenital heart disease.
- Children with cystic fibrosis and other congenital pulmonary diseases.

#### 2.2. Sample size

The sample size was calculated using the GRANMO v7.2, 2012 program for the study of paired proportions, accepting an alpha



#### created with mapchart.net

Figure 1. Countries considered in the study for having regions with an incidence of tuberculosis of 40 cases/100,000 inhabitants or greater.

risk of 0.05 and a beta risk of 0.2 in a two-sided test. It was estimated that 492 subjects are necessary to obtain a statistically significant difference considering an initial LTBI proportion of 0% and a final proportion of 2%. A drop-out rate of 20% is anticipated.

#### 2.3. Data collection

Baseline data collection: Eligible children will be offered to participate in the study during a programmed visit in a pre-travel health clinic or in a PCC. In the first visit, the parents or legal guardians will be interviewed to complete a questionnaire including socio-demographic, epidemiological, and clinical data. A tuberculin skin test (TST) will be performed and read 48 to 72 hours later. Figure 2 shows the study flowchart.

The TST will be made within 30 days prior to the trip. In BCG vaccinated children, TST will be performed and if the result is positive, a *QuantiFERON-Plus*© (QFT-Plus) test will be carried out to confirm the infection. Subsequently, if the QFT-Plus test is positive, the child will be excluded from the study and treated for LTBI.

Follow-up: A visit will be scheduled 8 to 12 weeks after returning from the trip. Here, a questionnaire with epidemiological and clinical data about the trip will be completed and a TST and QFT-Plus test will be simultaneously performed.

Children diagnosed with LTBI or TB, either at baseline or at follow-up, will receive treatment as per national guidelines, and relatives will be referred for contact tracing. Similarly, the investigators will verify the need for other preventive measures (malaria chemoprophylaxis, helminthiasis study, other immunizations, etc).

Data registration: The information collected in the questionnaires will be registered and managed in REDCap (Research Electronic Data Capture) tools hosted at Fundació de Docència I Recerca Mútua Terrassa. REDCap is a secure, web-based software platform designed to support data capture for research studies.  $^{\left[ 21,22\right] }$ 

#### 2.4. Outcomes

**2.4.1.** *Primary outcome.* The primary outcome is the diagnosis of LTBI and/or TB after travelling to a high TB incidence country in accordance with World Health Organization (WHO) guide-lines.<sup>[1]</sup> At the end of the study, patients will be classified as: "not infected; LTBI/TB disease; unknown/lost to follow-up". Table 2 shows study variables and timing of data collection.

#### 2.4.2. Secondary outcomes.

- 1. Sociodemographic data: sex, age, country of birth, country of birth of mother and father.
- Clinical data: weight and height (before and after travel), BCG vaccination, presence of BCG scar.
- 3. Epidemiological data: pre-travel visit date, travel date, posttravel visit date, return date of the travel, trip duration, travel country, number of people that lived in host home, travel environment (rural / urban / mixed), smokers in host home, contact with a person suspected of having TB.

#### 2.5. TST and QFT-Plus test procedures

Tuberculin Skin Test (TST): TST will be performed by intradermal injection of 2 UT of PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) and read after 48 to 72 hours. A positive test is defined as an induration greater than or equal to 10 mm according to recommendations from the *Agència de Salut Pública de Catalunya*<sup>[23]</sup> and WHO guidelines.<sup>[1]</sup>

QuantiFERON-TB Plus (QFT-Plus) (Cellestis, Victoria, Australia; QIAGEN, Dusseldorf, Germany): We will draw four ml of blood per child and interpret the QFT-Plus test according to manufacturer's instructions. Values  $\geq 0.35$  IU/ml in either TB1

## Table 1

### High and low tuberculosis incidence countries.

ountry/Territory	Estimated rate per 100,000 population	Number of cases	C
iqh tuberculosis incidence *			-
Afghanistan	189	70,000	
Algeria	69	29,000	
Angola	355	109,000	
Azerbaijan	63	6300	
Bangladesh	221	357,000	
Benin	56	6500	
Bhutan	149	1100	
		12.000	
Bolivia (Plurinational State of) Botswana	108	1	
	275	6200	
Brazil	45	95,000	
Brunei Darussalam	68	290	
Burkina Faso	48	9500	
Burundi	111	12,000	
Cabo Verde	46	250	
Cambodia	302	49,000	
Cameroon	186	47,000	
Central African Republic	540	25,000	
Chad	142	22,000	
China	61	866,000	
China, Hong Kong SAR	67	4900	
China, Macao SAR	60	380	
Congo	375	20,000	
Côte d'Ivoire	142	36,000	
Democratic People's Republic of Korea	513	131,000	
Democratic Republic of the Congo	321	270,000	
Djibouti	260	2500	
Dominican Republic	45	4800	
Ecuador	44	7400	
El Salvador	70	4500	
Equatorial Guinea	201	2600	
Eritrea	89	3100	
Eswatini	329	3700	
Ethiopia	151		
	54	165,000	
Fiji		480	
Gabon	525	11,000	
Gambia	174	4000	
Georgia	80	3200	
Ghana	148	44,000	
Greenland	100	56	
Guam	49	82	
Guinea	176	22,000	
Guinea-Bissau	361	6800	
Guyana	83	640	
Haiti	176	20,000	
India	199	2,690,000	
Indonesia	316	845,000	
Iraq	42	16,000	
Kazakhstan	68	12,000	
Kenya	292	150,000	
Kiribati	349	400	
Kyrgyzstan	116	7300	L
Lao People's Democratic Republic	162	11,000	
Lesotho	611	13,000	
Liberia	308	15,000	
Libya	40	2700	
Lithuania	40	1200	
Madagascar	233	61,000	
0			
Malawi	181	33,000	
Malaysia	92	29,000	
Mali	53	10,000	
Marshall Islands	434	250	1
Mauritania	93	4100	
		(continued)	t

		E	Га	b	le	
--	--	---	----	---	----	--

	Estimated rate	
Country/Territory	per 100,000 population	Number of cases
Micronesia (Federated States of)	108	120
Mongolia	428	14,000
Morocco	99	
		36,000
Mozambique	551	162,000
Myanmar	338	181,000
Namibia	524	13,000
Nauru	54	6
Nepal	151	42,000
Nicaragua	41	2600
Niger	87	19,000
Nigeria	219	429,000
Niue	71	1
Northern Mariana Islands	95	54
Pakistan	265	562,000
Palau	109	20
Panama	52	2200
Papua New Guinea	432	37,000
Paraguay	43	3000
Peru	123	39,000
Philippines	554	591,000
Republic of Korea	66	34,000
Republic of Moldova	86	3500
Romania		
	68	13,000
Russian Federation	54	79,000
Rwanda	59	7300
Sao Tome and Principe	124	260
Senegal	118	19,000
Sierra Leone	298	23,000
Singapore	47	2700
Solomon Islands	74	480
Somalia	262	39,000
South Africa	520	301,000
South Sudan	146	
		16,000
Sri Lanka	64	14,000
Sudan	71	30,000
Tajikistan	84	7600
Thailand	153	106,000
Timor-Leste	498	6300
Turkmenistan	46	2700
Tuvalu	270	31
Uganda	200	86,000
Ukraine	80	36,000
United Republic of Tanzania	253	142,000
Uzbekistan		
	70	23,000
Vanuatu	46	130
Venezuela (Bolivarian Republic of)	48	14,000
Viet Nam	182	174,000
Yemen	48	14,000
Zambia	346	60,000
Zimbabwe	210	30,000
Low tuberculosis incidence <sup>†</sup>		,
Argentina	27	12,000
Belize	30	110
Colombia	33	16,000
Egypt	12	12,000
Guatemala	26	4500
Honduras	37	3500
Suriname	38	220
Togo	36	2800
Tunisia	35	4000
Turkey	16	13,000
	10	13,000

timated incidence rate of 40 per 100,000 population or greater. timated incidence rate of less than 40 per 100,000 population. Source: World Health Organization (WHO) Tuberculosis burden estimates. https://www.who.int/tb/publications/global\_report/en/.




Figure 2. Timeline of study visits and procedures.

and/or TB2 antigen tubes will be considered positive.<sup>[24]</sup> In the case of QFT-Plus values  $\geq 0.2$  and < 0.35 (gray zone), the test will be repeated 4 to 8 weeks later. QFT-Plus can have a positive, negative or indeterminate result.

If TST and QFT-Plus results are discordant, the test with a negative result will be repeated 4 to 8 weeks later.

#### 2.6. Statistical analysis

Qualitative variables will be described using frequency tables, and quantitative variables will be determined using median, mean and interquartile range (IQR). We will use paired proportions for comparisons. The incidence rate of LTBI and TB will be estimated per individual/month and person/year per country visited and by

#### Table 2

#### Study variables and timing of data collection.

Characteristics	Type of response	Data collection	
		Baseline	Follow-up
Sociodemographic data			
Sex; age	Nominal; Quantitative (years)		
Country of birth of the child	Nominal		
Mother's country of origin	Nominal		
Father's country of origin	Nominal		
Clinical data			
Weight; height	Quantitative (Kg); (cm)		
BCG Vaccination	Nominal (Yes/No type)		
Presence of BCG scar	Nominal (Yes/No type)		
Infection study			
Tuberculin test date	Date (yyyy-mm-dd)		
Tuberculin test result	Quantitative (mm)		
QFT-Plus date	Date (yyyy-mm-dd)		
QFT-Plus result	Quantitative (UI/mI))		
Final diagnosis	Nominal		
Epidemiological data			
Date of visits	Date (yyyy-mm-dd)		
Age at visits	Quantitative (years)		
Travel country	Nominal		
Travel date (probable <sup>a</sup> /true <sup>b</sup> )	Date (yyyy-mm-dd)	a	■ <sup>b</sup>
Return date of the travel (probable <sup>a</sup> /true <sup>b</sup> )	Date (yyyy-mm-dd)	a	∎ <sup>b</sup>
Time between tuberculin test and travel date (probable <sup>a</sup> /true <sup>b</sup> )	Time in days	a	∎ b
Trip duration	Quantitative (days)		
Time between tuberculin test and return date	Time in days		
Number of people that lived in host home	Quantitative (number of people)		
Travel environment	Nominal (rural, urban, mixed)		
Smokers in host home	Nominal (Yes/No type)		
Contact with a person suspected of having TB	Nominal (Yes/No type)		

BCG = Bacillus Calmette-Guérin vaccine, QFT-Plus = QuantiFERON-plus test, TB = tuberculosis.

age group. To identify factors associated with presence of LTBI or TB, the Fisher exact test or Chi-square test and the Mann-Whitney test will be used for bivariate analyses, followed by analysis of logistic regression calculating odds ratios and 95% confidence intervals. A 5% type I error will be estimated. Data will be exported from the REDCap database to PASW Statistics 25 (SPSS Inc., Chicago, IL) for statistical analyses.

#### 2.7. Ethics

This study protocol (version 2, 01/02/2016) has been approved by the Clinical Research Ethics Committee of the *Hospital Universitari Mútua Terrassa* on 24/02/2016 (code 02/16) and by the Clinical Research Ethics Committee of the *Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina* (IDIAPJGol) on 25/04/2016 (code P16/094), in agreement with the Declaration of Helsinki/Tokyo. All parents or legal guardians of the participants will receive oral and written information about the study and Informed Consent will be obtained. Any amendment to the study protocol will be submitted to the ethical committees for approval.

The REDCap<sup>©</sup> database will be exclusively used by the team of researchers. The data included in the database used for statistical analyses will be anonymized and identified with internal codes of the project to avoid identification by the investigative team to guarantee confidentiality.

The results of the study will be published in scientific journals and will be presented in national and international meetings. The results will be communicated to participants in a meeting and via local and national media, and will also be disseminated to the general population.

#### 3. Discussion

This study aims to evaluate the risk of LTBI and TB in paediatric VFR travellers that live in Catalonia, a low incidence TB region.<sup>[20]</sup> The study will be conducted in primary care centres, specialized travel clinics and hospital paediatric departments of the public health-care system. The joint role of primary care and infectious disease specialists is crucial in the implementation of strategies aimed at the eradication of TB in this population.<sup>[25]</sup> To our knowledge, this is the first study to prospectively analyse collected data from VFR children.

The few studies published with adults to date suggest that in non-VFR travellers, the risk of infection is similar to the local annual risk of TB infection.<sup>[26]</sup> In contrast, studies conducted with the immigrant population suggest that a significant percentage of TB cases are related to recent travel to the country of origin.<sup>[27]</sup> In the case of children, a population group with higher susceptibility to develop TB after primary infection, a case-control study from California reported an increased risk of LTBI in young paediatric VFR travellers and children of families that hosted visitors from countries with high TB incidence.<sup>[28]</sup>

Awareness of travel-associated risk of disease in VFR remains low, which might explain the scarce use of pre-travel health-care services by the immigrant population.<sup>[29]</sup> Moreover, the diversity of recommendations for different regions and countries demonstrates the limited information available on this topic.<sup>[30,31]</sup> Knowledge about the effectiveness of LTBI screening or BCG vaccination strategies also remains poor.<sup>[32]</sup> The implementation of strategies for the detection and treatment of LTBI cases should be prioritized to prevent new cases of TB in the paediatric and the adult population.<sup>[33]</sup>

Since state-level data are those usually published in official reports and regional incidence could vary significantly within the same country, a limitation of the study is the unavailability of data on regional incidence, which may hinder the assessment on the intensity of exposure to *M tuberculosis*.<sup>[17]</sup> In addition, due to the specific immigration patterns of Catalonia, some countries of origin will be overrepresented in our sample.

The lack of gold standard for LTBI diagnosis responds to its paucibacillary nature, the quiescent state of *M tuberculosis* and the localization in the mediastinal lymph nodes.<sup>[34]</sup> However, this is a universal limitation in all studies on this issue.

The low positive predictive value of the screening tests of LTBI in the general population constitutes another limitation. However, in low burden countries and among high risk groups such as immigrants and VFR travellers, tests may be useful for LTBI screening.<sup>[35]</sup>

Similarly, the TST and interferon- $\gamma$  release assays have well described limitations, which can hinder the interpretation of results and the calculation of incidence rates, especially in the case of discordant results.<sup>[36,37]</sup> Again, this is a universal limitation in all studies on this issue.

The study will implement and evaluate a new detection strategy and management of LTBI in VFR children in a country with a low incidence of TB. This strategy may prove useful to design public health policies in regions with low incidence of TB with significant numbers of VFR travellers.

#### **Acknowledgments**

The authors thank the tuberculosis prevention and control program from the *Agència de Salut Pública de Catalunya* for study support.

#### Author contributions

Conceptualization: Antoni Soriano-Arandes, Joan A. Caylà, Àngels Orcau, Antoni Noguera-Julian, Tomàs Maria Pérez-Porcuna.

- Data curation: Alessandra Queiroga Gonçalves, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez.
- Funding acquisition: Antoni Soriano-Arandes, Tomàs Maria Pérez-Porcuna.
- Investigation: Alessandra Queiroga Gonçalves, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez, Tomàs Maria Pérez-Porcuna.
- Methodology: Joan A. Caylà, Alessandra Queiroga Gonçalves, Àngels Orcau, Antoni Noguera-Julian.
- Project administration: Antoni Soriano-Arandes, Tomàs Maria Pérez-Porcuna.
- Supervision: Antoni Soriano-Arandes, Joan A. Caylà, Àngels Orcau, Antoni Noguera-Julian, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G. García-Lerín, Maria

Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez, Tomàs Maria Pérez-Porcuna.

- Visualization: Antoni Soriano-Arandes, Joan A. Caylà, Àngels Orcau, Antoni Noguera-Julian, Tomàs Maria Pérez-Porcuna.
- Writing original draft: Antoni Soriano-Arandes, Joan A. Caylà, Alessandra Queiroga Gonçalves, Antoni Noguera-Julian, Tomàs Maria Pérez-Porcuna.
- Writing review & editing: Àngels Orcau, Emma Padilla, Elisabet Solà-Segura, Neus Rius Gordillo, María Espiau, Mónica G. García-Lerín, Maria Àngels Rifà-Pujol, Jordi Gómez i Prat, Esperança Macia-Rieradevall, Andrea Martin-Nalda, Maria Eril-Rius, José Santos Santiago, Lídia Busquets-Poblet, Raisa Morales Martínez.

#### References

- World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management; 2018. Available in: http://www.who.int/tb/publications/2018/latent-tuberculosis-infec tion/en/ [access date February 22, 2020].
- [2] World Health Organization. Global tuberculosis report 2019; 2019. Available in: http://www.who.int/tb/publications/global\_report/en/ [access date May 21, 2020].
- [3] Vanden Driessche K, Persson A, Marais BJ, et al. Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013;2013:781320.
- [4] Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:636–47.
- [5] Thomas TA. Tuberculosis in Children. Pediatr Clin North Am 2017; 64:893–909.
- [6] Hoppe LE, Kettle R, Eisenhut M, et al. Tuberculosis-diagnosis, management, prevention, and control: summary of updated NICE guidance. BMJ 2016;352:h6747.
- [7] Cruz AT, Starke JR, Lobato MN. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr 2014;26:106–13.
- [8] Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2018. Demographics; 2019. Available in: https://www. cdc.gov/tb/statistics/reports/2018/demographics.htm [access date May 10, 2020].
- [9] European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe, 2019; 2019. Available in: https:// www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillanceand-monitoring-europe-2019 [access date April 5, 2020].
- [10] Boggild AK, Geduld J, Libman M, et al. Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet. J Travel Med 2019;26:tay117.
- [11] Farah MG, Meyer HE, Selmer R, et al. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol 2005;34:1005–11.
- [12] Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. JAMA 2008;300:405–12.
- [13] Schlagenhauf P, Weld L, Goorhuis A, et al. Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis 2015;15:55–64.
- [14] Zuckerman JN. Recent developments: travel medicine. BMJ 2002; 325:260–4.
- [15] Monge-Maillo B, Norman FF, Pérez-Molina JA, et al. Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants or both? A comparative analysis. Travel Med Infect Dis 2014;12:88–94.
- [16] Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. Travel Med Infect Dis 2011;9:192–203.

- [17] Elfrink F, van den Hoek A, Mensen ME, et al. Screening travellers to high-endemic countries for infection with Mycobacterium tuberculosis using interferon gamma release assay; a prospective study. BMC Infect Dis 2014;14:515.
- [18] Denholm JT, Thevarajan I. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. J Travel Med 2016;23: taw008.
- [19] Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon (release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230–9.
- [20] Agència de Salut Pública de Catalunya. Departament de Salut. Informe anual 2017. Situació epidemiològica i tendència de l'endèmia tuberculosa a Catalunya; 2019. Available in: https://canalsalut.gencat.cat/web/. content/\_A-Z/T/tuberculosi/documents\_prof/arxius/informe\_anual\_tu berculosi\_2017.pdf. [access date July 21, 2020].
- [21] Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
- [22] Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
- [23] Altet-Gómez N, Asensio O, Domínguez-Benítez JA, et al. Recomanacions per a la prevenció i el control de la tuberculosi pediàtrica a Catalunya; 2015. Available in: https://scientiasalut.gencat.cat/handle/11351/1519 [access date January 10, 2020].
- [24] Pai M, Riley LW, Colford JMJr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–76.
- [25] Hunziker T, Berger C, Staubli G, et al. Profile of travel-associated illness in children, Zürich, Switzerland. J Travel Med 2012;19:158–62.
- [26] Brown ML, Henderson SJ, Ferguson RW, et al. Revisiting tuberculosis risk in Peace Corps Volunteers, 2006-13. J Travel Med 2015;23:tav005.
- [27] Kik SV, Mensen M, Beltman M, et al. Risk of travelling to the country of origin for tuberculosis among immigrants living in a low-incidence country. Int J Tuberc Lung Dis 2011;15:38–43.
- [28] Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med 1998;158:1871–5.
- [29] Brophy J. Committee to Advise on Tropical Medicine, Travel (CATMAT)Summary of the Statement on International Travellers Who Intend to Visit Friends and Relatives. Can Commun Dis Rep 2015;41:89–99.
- [30] Jagger A, Reiter-Karam S, Hamada Y, et al. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ 2018;96:173–84F.
- [31] Bertoncello C, Ferro A, Ferraresso A, et al. LTBI among migrants by Mediterranean Sea: assessing prevalence and its variations according with different thresholds and diagnostic tools. A 10-month on-field experience. J Travel Med 2018;25:tay020.
- [32] Ritz N, Connell TG, Curtis N. To BCG or not to BCG? Preventing travelassociated tuberculosis in children. Vaccine 2008;26:5905–10.
- [33] World Health Organization. WHO End TB Strategy; 2015. Available in: https://www.who.int/tb/post2015\_strategy/en/ [access date December 27, 2019].
- [34] Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev 2014;27:3–20.
- [35] Brassard P, Steensma C, Cadieux L, et al. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics 2006;117:e148–56.
- [36] Perez-Porcuna TM, Pereira-da-Silva HD, Ascaso C, et al. Prevalence and diagnosis of latent tuberculosis infection in young children in the absence of a gold standard. PLoS One 2016;11:e0164181.
- [37] Thomas TA, Mondal D, Noor Z, et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. Pediatrics 2010;126:e1522–1529.